(NASDAQ: SLDB) Solid Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.86%.
Solid Biosciences's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast SLDB's revenue for 2024 to be $509,457,128, with the lowest SLDB revenue forecast at $509,457,128, and the highest SLDB revenue forecast at $509,457,128. On average, 1 Wall Street analysts forecast SLDB's revenue for 2025 to be $683,135,695, with the lowest SLDB revenue forecast at $683,135,695, and the highest SLDB revenue forecast at $683,135,695.
In 2027, SLDB is forecast to generate $1,752,223,760 in revenue, with the lowest revenue forecast at $1,752,223,760 and the highest revenue forecast at $1,752,223,760.